APO-QUETIAPINE 200 MG
QUETIAPINE (QUETIAPINE FUMARATE) : 200 MG · DIN 02313936 · APOTEX INC
Health Canada status: DORMANT
What is APO-QUETIAPINE?
APO-QUETIAPINE 200 MG contains QUETIAPINE (QUETIAPINE FUMARATE) : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02313936, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 26-Jun-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-QUETIAPINE used for?
Management of the manifestations of schizophrenia; monotherapy for the acute management of manic episodes associated with bipolar disorder.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02313936 |
|---|---|
| Brand name | APO-QUETIAPINE |
| Generic / active ingredient | QUETIAPINE (QUETIAPINE FUMARATE) : 200 MG |
| Manufacturer | APOTEX INC |
| Strength | 200 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AH04 QUETIAPINE |
| AHFS class | 28:16.08.04 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 26-Jun-2022 |
| Original market date | 2008-09-04 00:00:00 |
How is it administered?
Schizophrenia: Start 25 mg b.i.d., titrate to 300 mg/day by day 4-7. Bipolar Mania: Titrate from 100 mg/day (Day 1) up to 800 mg/day (Day 6). Administer with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (section 11 is listed in TOC but content not in snippet). Standard practice is 15-30°C.
How is it supplied?
Bottles of 100 and 500 tablets; blister packages of 30 tablets.
Contraindications
Hypersensitivity to quetiapine or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Increased mortality in elderly patients with dementia. Risk of Neuroleptic Malignant Syndrome, Tardive Dyskinesia, QT prolongation, hyperglycemia, and weight gain. Risk of orthostatic hypotension.
Is QUETIAPINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by JAMP PHARMA CORPORATION (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N05AH04 QUETIAPINE. 93 of 236 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-QUETIAPINE | 100 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02387808 |
| ACH-QUETIAPINE | 150 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02387816 |
| ACH-QUETIAPINE | 200 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02387824 |
| ACH-QUETIAPINE | 25 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02387794 |
| ACH-QUETIAPINE | 300 MG | TABLET (IMMEDIATE RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02387832 |
| ACH-QUETIAPINE FUMARATE XR | 150 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02450879 |
| ACH-QUETIAPINE FUMARATE XR | 200 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02450887 |
| ACH-QUETIAPINE FUMARATE XR | 300 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02450895 |
| ACH-QUETIAPINE FUMARATE XR | 400 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02450909 |
| ACH-QUETIAPINE FUMARATE XR | 50 MG | TABLET (EXTENDED-RELEASE) | ACCORD HEALTHCARE INC | MARKETED | DIN 02450860 |
Who else supplies QUETIAPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. QUETIAPINE appears in 7122 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.